

Practitioner's Docket No. MPI95-015P1RCPA1DV1RCEM

U.S.S.N. 09/801,089

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 20. (Canceled)

21. (Currently Amended) A method to identify outside-in or inside-out integrin mediated signaling comprising the step of determining whether the cytoplasmic domain of the β subunit of ~~an~~ the integrin is phosphorylated on tyrosine, ~~wherein the β subunit does not contain an ITAM motif~~, wherein a phosphorylated tyrosine in the cytoplasmic domain of the β subunit of the integrin indicates integrin-mediated outside-in or inside-out signaling.

22. (Currently Amended) The method of claim 21 comprising the steps of :

- a) preparing an extract of a cell expressing an integrin β-subunit,
- b) electrophoresing the extract using SDS electrophoresis, and
- c) analyzing the electrophoresed sample to determine whether ~~the a~~ tyrosine residue[[s]] in the cytoplasmic domain of the β subunit of said integrin ~~are~~ is phosphorylated.

23. (Previously Presented) The method of claim 22 wherein an anti-phosphotyrosine antibody is used in the analysis step c).

24. – 29. (Canceled)

30. (Previously Presented) The method of claim 22 wherein the extract is prepared with a high concentration of SDS.

31. (Canceled)

32. (Previously Presented) The method of claim 22 wherein the electrophoresis is 2D electrophoresis.

33. (Previously Presented) The method of claim 22 wherein the cell is a tumor cell.

34. (Previously Presented) The method of claim 33 wherein the tumor cell is a carcinoma cell.

35. (Previously Presented) The method of claim 22 wherein the cell is a platelet.

(Page 2 of 7)

Practitioner's Docket No. MPI95-015P1RCPA1DV1RCEM

U.S.S.N. 09/801,089

36. (Previously Presented) The method of claim 22 wherein the cell is an immune system cell.

37. (Previously Presented) The method of claim 36 wherein the immune system cell is selected from the group consisting of: a lymphocyte, a leukocyte, a monocyte, a macrophage, a granulocyte, a natural killer cell, and a neutrophil.

38. (Previously Presented) The method of claim 22 wherein the cell is an epithelial cell.

39. (Previously Presented) The method of claim 38 wherein the epithelial cell is a keratinocyte.

40. (Previously Presented) The method of claim 22 wherein the cell is a fibroblast.

41. (Currently Amended) The method of claim 22, wherein the cell expresses an integrin having a β subunit of an integrin selected from the group consisting of β3 integrin, β5 integrin, β6 integrin, β7 integrin, and β8 integrin.

42. (Previously Presented) The method of claim 22, wherein the cytoplasmic domain of the β subunit of the integrin is selected from the group consisting of the cytoplasmic domain of β3 integrin (SEQ ID NO:16), the cytoplasmic domain of β5 integrin (SEQ ID NO:19), the cytoplasmic domain of β6 integrin (SEQ ID NO:17), and the cytoplasmic domain of β7 integrin (SEQ ID NO:21).

43. (Currently Amended) A method to identify outside-in or inside-out integrin mediated signaling, wherein the integrin has a β3 subunit, comprising the step of determining whether a tyrosine residue in the cytoplasmic domain of β3 subunit of the integrin (SEQ ID NO:16) is phosphorylated, wherein a phosphorylated tyrosine residue in the cytoplasmic domain of β3 integrin indicates integrin-mediated outside-in or inside-out signaling, wherein the integrin has a β3 subunit.

44. (Currently Amended) The method of claim 43, comprising the steps of:

- a) preparing an extract of a cell expressing β3 an integrin, wherein the integrin has a β3 subunit, in a high concentration of SDS;
- b) performing 2D electrophoresis on the extract; and
- c) analyzing the electrophoresed extract with an anti-phosphotyrosine antibody to determine whether a tyrosine residue in the cytoplasmic domain of β3 integrin is phosphorylated.

(Page 3 of 7)